Advertisement
Advertisement
KYNB
K
Kyntra Bio, Inc. Common Stock
6.99
USDSponsored
+0.15
+2.12%
Mar 04, 15:58 UTC -5
Closed
After-Market
6.99
0.00
0.00%
KYNB Earnings Reports
Positive Surprise Ratio
KYNB beat 1 of 1 last estimates.
100%
Next Report
Date of Next Report
Mar 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.45M
/-$3.96
Implied change from Q3 25 (Revenue/ EPS)
+35.08%
/+21.85%
Implied change from Q4 24 (Revenue/ EPS)
--
/-188.00%
Kyntra Bio, Inc. Common Stock earnings per share and revenue
On Nov 10, 2025, KYNB reported earnings of -3.25 USD per share (EPS) for Q3 25, beating the estimate of -4.08 USD, resulting in a 20.44% surprise. Revenue reached 1.08 million, compared to an expected 1.67 million, with a -35.68% difference.
Looking ahead to Q4 25, -- analysts forecast an EPS of -3.96 USD, with revenue projected to reach 1.45 million USD, implying an increase of 21.85% EPS, and increase of 35.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
GT Biopharma Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$0.22
Actual
-$0.02
Surprise
+91.09%
Bone Biologics Corp Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.14
Surprise
+59.63%
Belite Bio, Inc - ADR
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.38
Surprise
+31.80%
Scholar Rock Holding Corporation Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.90
Actual
-$0.88
Surprise
+3.09%
Apogee Therapeutics, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$1.07
Actual
-$1.03
Surprise
+4.31%
uniQure N.V.
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$0.96
Actual
-$0.56
Surprise
+41.97%
Oculis Holding AG Ordinary shares
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.42
Actual
-$0.39
Surprise
+6.57%
Biohaven Ltd.
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$1.31
Actual
-$1.21
Surprise
+8.00%
EyePoint, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.76
Actual
-$0.81
Surprise
-6.20%
Ocugen, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.06
Surprise
-1.35%
FAQ
What were Kyntra Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kyntra Bio, Inc. Common Stock reported EPS of -$3.25, beating estimates by 20.44%, and revenue of $1.08M, -35.68% below expectations.
How did the market react to Kyntra Bio, Inc. Common Stock's Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Kyntra Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 16, 2026.
What are the forecasts for Kyntra Bio, Inc. Common Stock's next earnings report?
Based on --
analysts, Kyntra Bio, Inc. Common Stock is expected to report EPS of -$3.96 and revenue of $1.45M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement